Central regions | Technology & innovation

Russian company develops new leukemia drug candidate

25 Apr '14
Fusion Pharma, a biotech developer at the Skolkovo innovation hub outside Moscow, has come up with a new leukemia drug candidate and is gearing up for clinical trials, the Skolkovo Foundation website announced.

“We will do our best to launch the clinical trials of the PF-114 candidate as soon as possible,” the Foundation cited a statement by Germes Chilov, Ph.D. in chemistry, the CEO of Fusion Pharma.

The new drug candidate was presented last week in Moscow at the 2nd Hematologists Congress of Russia.

According to Prof. Ann Turkina, M.D., a Russian specialist in chemotherapy of myeloproliferative diseases, “the coming of a new drug to treat chronic myeloleucosis is a timely development, as at the moment there are many patients resistant to currently available therapies.”
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations:

Tags: Skolkovo (323) / leukemia (2) / PF 114 (0) / Fusion Pharma (0) /

Latest News: Central regions
16 Jan '18 | Finance, business | Technology & innovation
15 Jan '18 | Technology & innovation
11 Jan '18 | Finance, business | Technology & innovation
9 Jan '18 | Technology & innovation | Retail, FMCG
 

Feature stories

21 Nov '17
Russian scientists have come up with what they say is...
7 Sep '17
26 Jul '17
Scientists at Tomsk Polytechnic (TPU) in Siberia have...
Search (News archive - 21208)
Advertising
Independent Software Developers Forum
Advertising
Marchmont News

Latest News

19 Jan '18
Scientists in Samara have come up with a new method...
18 Jan '18
Scientists in St. Petersburg have partnered with...
17 Jan '18
Russian scientists in partnership with their Korean...

Most read stories from last week

16 Jan '18
Primer Capital, a Russian venture fund, has invested...
17 Jan '18
Russian scientists in partnership with their Korean...
18 Jan '18
Scientists in St. Petersburg have partnered with...